Sign in
DMAC Stock Price, Chart, Stats & News
DiaMedica Therapeutics Inc.
Save
304.44M
Market cap
–
Current P/E
–
Forward P/E
DMAC chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.08% |
ROA | -55.96% |
ROE | -83.21% |
D/E | 0.01x |
Interest coverage ratio | – |
DMAC valuation
P/E | – |
P/S | – |
P/B | 6.53x |
P/CF | -12.13x |
P/FCF | -12.71x |
P/OCF | -12.13x |
PEG | 3.64x |
EV multiple | -10.94x |
About
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients.
Similar securities
Based on sector and market capitalization
Report issue